Call for Speaker Proposals
第3届
Cancer Biologics
-抗癌生物制剂学会-
复合体、多特异性、生物标志及最新的方法
2月21日～23日
迎接第3年的此学会，成为能在癌治疗药创药的重要领域学习的宝贵机会，采用强有力的标的设定功能和实现效应功能（effector function）的最新工学方法进行临床前开发与转译（translational）研究、以及临床的进展等主题。此外，亦聚焦于抗体药物复合体、多特异性产品、并用疗法、免疫疗法、疫苗等，检讨因应核酸生物制剂和癌干细胞标的化新领域的最新方法、克服传递和肿瘤渗透课题的手段等。
Who should attend: VPs, Directors, CEOs, CSOs and Scientists from Large Pharma, Biotechs and Academia in such fields as R&D, Product Development, Translational Medicine, Protein Engineering, Target Discovery
Topics will include, but are not limited to advances in the following:
- Advances with antibody-drug conjugates
- Bi- and multi-specific biotherapeutics
- Combination therapies
- Nucleic acid therapies (RNAi and siRNA)
- Immunotherapies, vaccines and adoptive T cell therapy
- Targeting cancer stem cells
- Identification of novel targets
- Novel engineering and platforms
- Penetration and delivery to solid tumors
- Translational and clinical biomarkers
- Pre-clinical and clinical advances
- Strategies for regulatory approval, licensing and success in the market
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
